Experimentelle Untersuchungen und klinische Evidenz der Insulinpumpentherapie (CSII)

Zusammenfassung

Die Insulinpumpentherapie (Continuierliche Subcutane Insulin Infusion – CSII) ist eine etablierte Therapieform für die Insulin-Behandlung von Patien­ten mit Typ-1-Diabetes. Eine subtile Einstellung vorausgesetzt, profitieren die Patienten nach Umstellung von der ICT / MDI[1] auf die CSII von der Verbesserung des HbA1c-Wertes und / oder der Abnahme der Hypoglykämierate. Im Weiteren ist von der verbesserten Stoffwechsel­lage eine verminderte Progredienz diabetischer Folgeerkrankungen zu erwarten. Die CSII wird ­begleitet von einer großen Anzahl experimenteller Untersuchungen. Metaanalysen von randomisierten, kontrollierten klinischen Studien belegen die therapeutische Evidenz der Insulinpumpenbehandlung. 

Abstract

Continuous subcutaneous insulin infusion (CSII) is an established way of insulin therapy for pa­tients with type 1 diabetes. After correct insulin adjustment the patients on CSII experienced an improvement of HbA1c – and / or the decreasing rate of hypoglycemic reactions. On the long term an improved metabolic situation will lead to a ­reduction of long-term diabetic complications. The CSII has been studied in many experimental investigations. Meta-analyses of clinical trials have proved the therapeutic evidence of CSII. 

Typ-1-Diabetes - Insulinpumpentherapie (CSII) - Meta-Analysen - Evidenz der CSII - Hypoglykämierrate - HbA_1c

type 1 diabetes - continuous subcutaneous insulin infusion (CSII) - meta-analyses - clinical evidence - rate of hypoglycemic reactions - HbA1c

Literatur

• 1 Henrichs H R. Diabetestherapie mit Insulinpumpen. ISBN 3-89599-650-5; UNI-MED Verlag: 2003
• 2 Henrichs H R. Who should access Insulin pump treatment?. IDF-TWAS-Meeting Warzaw 2006. www.idf.org/webdata/docs/Presentation%20Henrichs%20Who%20should%20access%20pump%20therapy.ppt
• 3 Bode B. Pump therapy.  Diabetic Medicine. 2006;  23 (Suppl. 4) 426-427
• 4 Koivisto V A, Yki-Jarvinen H, Helve E et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII.  Diabetes. 1986;  35 78-82
• 5 Bode B W, Steed R D, Davidson P C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes.  Diabetes Care. 1996;  19 324-327
• 6 Aragona M, Giannarelli R, Coppelli A et al. Improvement of retinopathy in Type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII).  Diabetes Metabol. 2003;  29 235
• 7 Lüddeke H J, Hofmann W, Guder W G et al. Urinary albumin concentration in 52 CSII treated type 1 diabetic patients during a follow-up of 4 years.  Diabetes und Stoffwechsel. 2002;  11 (Suppl. 1) 115
• 8 Linkeschova R, Raoul M, Bott U et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.  Diabetic Medicine. 2002;  19 746-751
• 9 Doyle E A, Weinzimer S A, Steffen A T et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injection using insulin Glargine.  Diabetes Care. 2004;  27 1554-1558
• 10 Vortherms J, Klinkert C, Lotz N et al. Insulinpumpentherapie bei Kindern und Jugendlichen mit schwerwiegenden Verhaltensauffälligkeiten.  Diabetes und Stoffwechsel. 2001;  10 (Suppl. 1) 56
• 11 Knight S, Northam E, Donath S et al. Improvements in cognition, mood and behaviour following commencement of continuous subcutane­ous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study.  Diabetologia. 2009;  52 193-198
• 12 Danne T, Lange K, Kordonouri O. New developments in the treatment of type 1 diabetes in children.  Arch Dis Child. 2007;  92 1015-1019
• 13 Holder M, Ludwig-Seibold C, Lilienthal E für die DPV-Wiss-Initiative et al. Trends in der Insulinpumpentherapie bei Kindern, Jugendlichen und jungen Erwachsenen mit Typ-1-Diabetes von 1995–2006: Daten der DPV-Initiative.  Diabetologie & Stoffwechsel. 2007;  2 169-174
• 14 Pickup J, Sutten A J. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.  Diabetic Medicine. 2008;  25 765-774
• 15 Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.  Diabetologia. 2008;  51 941-951
• 16 NICE CSII Guidance TA151 .Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. Review of technology appraisal guidance 57, Issue Date July 2008: http://www.nice.org.uk/ta151
• 17 Hoogma R PL, Hammond P J, Gomis R on behalf of the 5-Nations Study Group et al.,. Comparison of the effects continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.  Diabetes Medicine. 2005;  23 141-147
• 18 Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis.  Diabetes Care. 2003;  26 1079-1087
• 19 Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes.  Diabetes Care. 2002;  25 593-598
• 20 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  The New England Journal of Medicine. 1993;  14 977-986
• 21 Unger H, Henrichs H R. DCCT 1992 (Diabetes Control and Complications Trial) – Zum Stand der US-amerikanischen Großstudie über den Zusammenhang zwischen Einstellungsqualität und Diabeteskomplikationen.  Diabetes und Stoffwechsel. 1992;  1 286-289
• 22 The Diabetes Control and Complications Trial Research Group . The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial.  Diabetes. 1995;  44 968-983
• 23 Eeg-Olofsson K, Cederholm J, Nilsson P M for the Steering Committee of the Swedish National Diabetes Register Glycemic and Risk Factor Control in Type 1 Diabetes et al.,. Results from 13 612 patients in a national diabetes register.  Diabetes Care. 2007;  30 496-502
• 24 Behre A, Ehren M, Reinsch B et al. Erste Erfahrungen mit kontinuier­lichem Glukose-Monitoring unter Klinikbedingungen.  Diabetes und Stoffwechsel. 2001;  10 (Suppl. 1) 126
• 25 Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials.  BMJ. 2002;  324 1-6
• 26 Kilpatrick E S, Rigby A S, Atkin S L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.  Diabetes Care. 2006;  29 1486-1490
• 27 Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.  JAMA. 2006;  295 1681-1687
• 28 Monnier L, Colette C, Leiter L et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.  Diabetes Care. 2007;  30 185-186
• 29 The Diabetes Research in Children Network (DirecNet) Study Group . The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.  Diabetes Care. 2007;  30 185
• 30 Hirsch I B, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?.  Journal of Diabetes and Its Complications. 2005;  19 178-181
• 31 Ceriello A, Kumar S, Piconi L et al. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes.  Diabetes Care. 2007;  30 649-654
• 32 Wentholt I ME, Kulik W, Michels R PJ et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes.  Diabetologia. 2008;  51 183-190
• 33 The Diabetes Control and Complications Trial Research Group . Hypoglycemia in the Diabetes Control and Complications Trial.  Diabetes. 1997;  46 271-286
• 34 Retnakaran R, DeVries H J, Hanaire-Broutin H et al. Continuous subcutaneous insulin infusion versus multiple daily injections.  Diabetes Care. 2005;  28 1835-1836
• 35 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen K F et al. Rapid tight­ening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study.  BMJ. 1985;  290 811-815
• 36 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen K F. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study.  BMJ. 1986;  293 1195-1199
• 37 Austenat E, Würzner M, Semmler S et al. CSII Is Superior to MDI for type 1 diabetes under real world conditions in clinical endpoints.  Diabetes. 2006;  55 (Suppl. 1) A 459
• 38 Lauritzen T, Pramming S, Deckert T et al. Pharmacokinetics of continuous subcutaneous insulin infusion.  Diabetologia. 1983;  24 326-329
• 39 Heise T, Nosek L, Biilmann Ronn B et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.  Diabetes. 2004;  53 1614-1620
• 40 Chase H P, Saib S Z, MacKenzie T et al. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with Type 1 diabetes.  Diabetic Medicine. 2002;  19 317-321
• 41 Lee M S, Cao M, Sajid A et al. The dual-wave bolus feature in CSII controls prolonged post-prandial hyperglycemia better than standard bolus in type 1 diabetes.  Diabetes. 2003;  52 (Suppl. 1) A 138
• 42 Jones S M, Quarry J L, Caldwell-McMillan M et al. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system.  Diabetes Technology & Therapeutics. 2005;  7 233-240
• 43 O’Connell M A, Gilbertson H R, Donath S M et al. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy.  Diabetes Care. 2008;  31 1491-1495
• 44 Pankowska E, Szypowska A, Lipka M et al. Three kind of mealtime insulin administration and metabolic control in diabetic children on insulin pumps.  Diabetologia. 2008;  51 (Suppl. 1) 381
• 45 Morrison G, Purewal T S, Weston P J. Intensive management with CSII can prevent hospital admissions of patients with gastroparesis.  Diabetologia. 2006;  49 (Suppl. 1) 677-678
• 46 Gross T M, Kayne D, King A et al. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy.  Diabetes Technology & Therapeutics. 2003;  5 365-369
• 47 Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).  Diabetic Medicine. 2008;  25 1036-1042
• 48 Jankovec Z. Frequency of available insulin pump functions use by patients with diabetes mellitus. 1st ATTD Meeting, Prague 2008: Proceedings 112
• 49 Liebl A, Krinelke L. Long-term results of insulin pump therapy (CSII) in adolescents and adults with type 1 diabetes mellitus in Germany.  Diabetologia Polska. 2003;  10 179-185
• 50 Zinman B, Chiasson J L, Tildesley H et al. Insulin lispro in CSII: results of a double-blind crossover study.  Diabetes. 1997;  46 440-443
• 51 Bode B W, Steed R D, Davidson P C. Continuous subcutaneous insulin ­infusion (CSII): a study comparing lispro to regular human insulin.  Diabetes. 1997;  46 (Suppl.) A 167
• 52 Renard E, Vague V, Pinget M et al. SC Infusion of insulin Lispro vs regular insulin by portable pumps: significant improvement of HbA1c and blood glucose stability under insulin Lispro.  Diabetes. 1997;  46 (Suppl. 1) 419
• 53 Reichel A, Rietzsch H, Köhler H J et al. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.  Exp Clin Endocrinol Diabetes.. 1998;  106 168-172
• 54 Guerci B, Meyer L, Salle A S et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interrup­tion of a continuous subcutaneous insulin infusion in type 1 diabetic ­patients.  Journal of Clinical Endocrinology & Metabolism. 1999;  84 2673-2678
• 55 Schartmann U, Larbig M, Schone E et al. 3-Hydroxybutyrate monitoring by means of a hand-held device after interruption of insulin pump therapy.  Diabetologia. 2000;  43 (Suppl. 1) A 208
• 56 Attila N, Holcombe J, Jones T W et al. Comparison of human regular and Lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.  Diabetes Care. 1998;  21 817-821
• 57 Renner R, Pfutzner A, Trautmann M et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog – CSII Study Group.  Diabetes Care. 1999;  22 784-788
• 58 Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis.  Diabetic Medicine. 2003;  20 863-866
• 59 Schmauss S, König A, Landgraf R. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?.  Diabet Med. 1998;  15 247-249
• 60 Linkeschova R, Spraul M, Jatzkowski E et al. Quality of life, treatment ­satisfaction and diabetes control on insulin Lispro and regular human insulin during CSII: a randomised double-blind crossover study.  Diabetes Metabol. 2003;  29 226
• 61 Schäfermeyer M T, Jatzkowksi E, Linkeschova R et al. Insulinpumpentherapie mit Insulin Lispro versus Normalinsulin bei Diabetes mellitus Typ 1 – Doppelblinde Cross-over-Studie unter Einbeziehung des ContinuousGlucose Monitoring System (CGMS).  Diabetologie. 2006;  1 137
• 62 Bode B W, Weinstein R, Bell D et al. Comparison of insulin Aspart with buffered regular insulin and insulin Lispro in continuous subcutaneous insulin infusion.  Diabetes Care. 2002;  25 439-444
• 63 Hanaire-Broutin H, Schumiki D-M, Hoogma R PLM et al. Safety of insulin Glulisine compared with insulin Aspart administered by continuous subcutaneous insulin infusion (CSII).  Diabetes. 2004;  53 (Suppl. 2) A4
• 64 Lepore G, Dodesini A R, Nosari I et al. Both continuous subcutaneous ­insulin infusion and a multiple daily insulin injection regimen with Glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.  Diabetes Care. 2003;  26 1321-1324
• 65 Lepore G, Dodesini A R, Nosari I et al. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection treatment.  Diabetes Metab. 2004;  17 84-89
• 66 Bolli G, Capani F, Home P D et al. Comparison of a multiple daily injection regimen with once-daily insulin Glargine basal insulin and mealtime Lispro, to continuous subcutaneous insulin infusion: a ran­domised, open, parallel study.  Diabetes. 2004;  53 (Suppl. 2) A107
• 67 Pickup J C, Kidd J, Burmiston D et al. Effectiveness of continuous sub­cutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes.  Practical Diabetes International. 2005;  22 10-14
• 68 The EQuality1 Study Group . Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous sub­cutaneous insulin infusion and multiple daily injections.  Diabetic Medicine. 2008;  25 213-220
• 69 Schottenfeld-Naor Y, Galatzer A, Karp M et al. Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients.  Isr J Med Sci. 1985;  21 822-828
• 70 Shapiro J, Wigg D, Charles M A et al. Personality and family profiles of chronic insulin-dependent diabetic patients using portable insulin ­infusion pump therapy: a preliminary investigation.  Diabetes Care. 1984;  7 137-142
• 71 Boland E A, Grey M, Oesterle A et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.  Diabetes Care. 22;  1999 1779-1784
• 72 Herman W H, Ilag L L, Johnson S L et al. Clinical trial of continuous sub­cutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.  Diabetes Care. 2005;  28 1568-1573
• 73 Edelman S V, Bode B W, Bailey T S et al. Continuous subcutaneous insulin infusion in patients with type 2 diabetes safely improved glycemic ­control using a simple insulin dosing regimen.  Diabetes. 2009;  58 (Suppl. 1) A113
• 74 Li Y, Xu W, Liao Z, Chen X et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function.  Diabetes Care. 2004;  27 2597-2602
• 75 Choi S B, Lee S M, Kim D Y et al. Changes in adipokine profiles in type 2 diabetics treated with long-term continuous subcutaneous insulin ­infusion.  Diabetes. 2006;  55 (Suppl. 1) A 97
• 76 Jankovec Z, Cechurova D, Krcma M et al. The influence of insulin pump treatment on metabolic syndrome parameters in type 2 diabetic patients.  Diabetes. 2006;  55 (Suppl. 1) A 142-A 143
• 77 Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
• 78 Chen H-S, Hsiao L-C, Wu T-E et al. Beneficial effects of insulin on glycem­ic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.  Diabetes Care. 2008;  31 1927-1932
• 79 Ilkova H, Glaser B, Tunckale A et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Care. 1997;  20 1353-1356
• 80 Noh Y-H, Lee J-H, Lee J-H et al. Long-term continuous subcutaneous ­insulin infusion treatment improved insulinogenic index and proinsulin-to-insulin ratio in longstanding type 2 diabetic patients.  Diabetes. 2009;  58 (Suppl. 1) A61
• 81 Zhang B, Chen Y, Yang Z et al. The role of acute glucagon response in long-term remission of newly-diagnosed type 2 diabetes induced by short-term insulin intensive treatment.  Diabetes. 2009;  58 (Suppl. 1) A62
• 82 Raskin P, Bode B W, Marks J B et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. A randomized, parallel-group, 24-week study.  Diabetes Care. 2003;  26 2598-2603
• 83 The ACCORD Study Group . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
• 84 Gill G V, Woodward A, Casson I F et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the ‘dead in bed’ syndrome revisited.  Diabetologia. 2009;  52 42-45
• 85 Sozialmedizinische Expertengruppe .„Versorgungsstrukturen“ (SEG-3) der MDK-Gemeinschaft Sozialmedizinische Stellungnahme zur Behandlung des Diabetes mellitus mit externen Insulinpumpen. April 2006
• 86 Halvorson M, Carpenter S, Kaiserman K et al. A Pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump.  J Pediatr. 2007;  150 103-105
• 87 Petrovski G, Dimitrovski C, Milenkovic T. Insulin pump therapy with continuous glucose monitoring improves metabolic control in brittle type 1 diabetes.  Prilozi Odd Biol Med Nauki. 2008;  28 129-135
• 88 Hirsch I B, Abelseth J, Bode B W et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.  Diabetes Technology & Therapeutics. 2008;  10 377-383
• 89 The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group . Continuous glucose monitoring and intensive treatment of type 1 diabetes.  NEJM. 2008;  359 1464-1476
• 90 Buckingham B A, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension.  Diabetes Technology & Therapeutics. 2009;  11 93-97

1 MDI (multiple daily insulin injections), in der englischsprachigen Literatur synonym verwendet für ICT (sogenannte intensivierte conventionelle Insulintherapie)